These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 20122111)

  • 1. Governance of nanotechnology and nanomaterials: principles, regulation, and renegotiating the social contract.
    Kimbrell GA
    J Law Med Ethics; 2009; 37(4):706-23. PubMed ID: 20122111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing U.S. oversight strategies for nanobiotechnology: learning from past oversight experiences.
    Paradise J; Wolf SM; Kuzma J; Kuzhabekova A; Tisdale AW; Kokkoli E; Ramachandran G
    J Law Med Ethics; 2009; 37(4):688-705. PubMed ID: 20122110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Science, ethics, and the "problems" of governing nanotechnologies.
    Hogle LF
    J Law Med Ethics; 2009; 37(4):749-58. PubMed ID: 20122114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating oversight systems for emerging technologies: a case study of genetically engineered organisms.
    Kuzma J; Najmaie P; Larson J
    J Law Med Ethics; 2009; 37(4):546-86. PubMed ID: 20122100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What does the history of technology regulation teach us about nano oversight?
    Marchant GE; Sylvester DJ; Abbott KW
    J Law Med Ethics; 2009; 37(4):724-31. PubMed ID: 20122112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction: The challenge of developing oversight approaches to nanobiotechnology.
    Paradise J; Wolf SM; Kuzma J; Ramachandran G; Kokkoli E
    J Law Med Ethics; 2009; 37(4):543-5. PubMed ID: 20122099
    [No Abstract]   [Full Text] [Related]  

  • 7. Commentary: Emerging technologies oversight: research, regulation, and commercialization.
    Johnson R
    J Law Med Ethics; 2009; 37(4):587-93. PubMed ID: 20122101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transnational models for regulation of nanotechnology.
    Marchant GE; Sylvester DJ
    J Law Med Ethics; 2006; 34(4):714-25. PubMed ID: 17199813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in governance of converging technologies integrated from the nanoscale.
    Roco MC
    Ann N Y Acad Sci; 2006 Dec; 1093():1-23. PubMed ID: 17312249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commentary: Is it possible to determine the extent to which informational asymmetries and prejudice bias responses?
    Hurley T
    J Law Med Ethics; 2009; 37(4):594-7. PubMed ID: 20122102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Problem formulation and option assessment (PFOA) linking governance and environmental risk assessment for technologies: a methodology for problem analysis of nanotechnologies and genetically engineered organisms.
    Nelson KC; Andow DA; Banker MJ
    J Law Med Ethics; 2009; 37(4):732-48. PubMed ID: 20122113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technology: Nanomaterials need flexible regulation.
    Wickson F
    Nature; 2011 Aug; 476(7360):283. PubMed ID: 21850092
    [No Abstract]   [Full Text] [Related]  

  • 13. Review of the OSHA framework for oversight of occupational environments.
    Choi JY; Ramachandran G
    J Law Med Ethics; 2009; 37(4):633-50. PubMed ID: 20122106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are environmental regulations keeping up with innovation? A case study of the nanotechnology industry.
    Fairbrother A; Fairbrother JR
    Ecotoxicol Environ Saf; 2009 Jul; 72(5):1327-30. PubMed ID: 19423165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards a more effective and efficient governance and regulation of nanomaterials.
    Teunenbroek TV; Baker J; Dijkzeul A
    Part Fibre Toxicol; 2017 Dec; 14(1):54. PubMed ID: 29258600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulating small things: genes, gametes and nanotechnology.
    Bennett B
    J Law Med; 2007 Aug; 15(1):153-60. PubMed ID: 17902497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Necessity and approach to integrated nanomaterial legislation and governance.
    Wang J; Gerlach JD; Savage N; Cobb GP
    Sci Total Environ; 2013 Jan; 442():56-62. PubMed ID: 23178764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corporate social responsibility for nanotechnology oversight.
    Kuzma J; Kuzhabekova A
    Med Health Care Philos; 2011 Nov; 14(4):407-19. PubMed ID: 21626458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Commentary: Who's afraid of the RAC? Lessons from the oversight of controversial science.
    Kahn JP
    J Law Med Ethics; 2009; 37(4):685-7. PubMed ID: 20122109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuating risks through regulation: issues for nanotechnology in India.
    Barpujari I
    J Biomed Nanotechnol; 2011 Feb; 7(1):85-6. PubMed ID: 21485816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.